| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Renal Cell | 110 | 2024 | 3130 | 8.870 |
Why?
|
| Kidney Neoplasms | 103 | 2024 | 4245 | 7.270 |
Why?
|
| Carbonic Anhydrases | 9 | 2024 | 115 | 2.090 |
Why?
|
| Prostate | 16 | 2022 | 1773 | 1.280 |
Why?
|
| Tumor Suppressor Proteins | 23 | 2021 | 2848 | 1.180 |
Why?
|
| Antigens, Neoplasm | 11 | 2024 | 1987 | 1.170 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 11 | 2022 | 290 | 1.120 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 13 | 2021 | 1039 | 1.040 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 11 | 2022 | 1114 | 0.990 |
Why?
|
| Endogenous Retroviruses | 2 | 2023 | 112 | 0.920 |
Why?
|
| Prostatic Neoplasms | 32 | 2021 | 11074 | 0.810 |
Why?
|
| Gene Expression Regulation, Neoplastic | 35 | 2022 | 8426 | 0.810 |
Why?
|
| Urologic Neoplasms | 5 | 2019 | 316 | 0.780 |
Why?
|
| Protein Kinase Inhibitors | 14 | 2022 | 5529 | 0.740 |
Why?
|
| Trans-Activators | 9 | 2015 | 2924 | 0.710 |
Why?
|
| Small Cell Lung Carcinoma | 5 | 2023 | 388 | 0.710 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 5 | 2017 | 627 | 0.660 |
Why?
|
| Carcinoma, Transitional Cell | 5 | 2019 | 802 | 0.650 |
Why?
|
| Mutation | 31 | 2022 | 29784 | 0.630 |
Why?
|
| PTEN Phosphohydrolase | 18 | 2022 | 1143 | 0.620 |
Why?
|
| Interleukin-2 | 6 | 2016 | 1904 | 0.600 |
Why?
|
| Anilides | 4 | 2022 | 405 | 0.590 |
Why?
|
| Viral Envelope Proteins | 1 | 2020 | 635 | 0.580 |
Why?
|
| Niacinamide | 8 | 2017 | 416 | 0.570 |
Why?
|
| Neoplasm Metastasis | 20 | 2019 | 4841 | 0.570 |
Why?
|
| Pyridines | 11 | 2022 | 2822 | 0.570 |
Why?
|
| Prognosis | 33 | 2023 | 29050 | 0.560 |
Why?
|
| Immunohistochemistry | 32 | 2021 | 11368 | 0.560 |
Why?
|
| TOR Serine-Threonine Kinases | 11 | 2020 | 2108 | 0.560 |
Why?
|
| Phosphoproteins | 6 | 2013 | 2440 | 0.550 |
Why?
|
| Stem Cells | 7 | 2015 | 3567 | 0.540 |
Why?
|
| Phenylurea Compounds | 8 | 2017 | 527 | 0.530 |
Why?
|
| Genes, Tumor Suppressor | 12 | 2021 | 1097 | 0.500 |
Why?
|
| Benzenesulfonates | 6 | 2011 | 169 | 0.500 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 15 | 2022 | 11493 | 0.500 |
Why?
|
| Tumor Suppressor Protein p53 | 8 | 2022 | 2948 | 0.490 |
Why?
|
| Cell Line, Tumor | 42 | 2022 | 16687 | 0.480 |
Why?
|
| Antineoplastic Agents | 21 | 2020 | 13668 | 0.470 |
Why?
|
| Ubiquitin Thiolesterase | 5 | 2021 | 449 | 0.470 |
Why?
|
| Transcription Factors | 24 | 2023 | 12207 | 0.460 |
Why?
|
| Urinary Bladder Neoplasms | 6 | 2017 | 2237 | 0.450 |
Why?
|
| Humans | 204 | 2024 | 744220 | 0.440 |
Why?
|
| Cell Proliferation | 19 | 2018 | 10480 | 0.430 |
Why?
|
| Gene Dosage | 5 | 2014 | 1251 | 0.430 |
Why?
|
| Carcinoma, Papillary | 3 | 2015 | 783 | 0.430 |
Why?
|
| Gene Expression Profiling | 20 | 2021 | 9438 | 0.420 |
Why?
|
| Proto-Oncogene Proteins c-met | 4 | 2020 | 578 | 0.410 |
Why?
|
| Neoplastic Stem Cells | 2 | 2013 | 1376 | 0.410 |
Why?
|
| Angiogenesis Inhibitors | 8 | 2016 | 2038 | 0.400 |
Why?
|
| Mice | 72 | 2024 | 81178 | 0.390 |
Why?
|
| Neoplasm Proteins | 5 | 2019 | 3703 | 0.390 |
Why?
|
| Sulfonamides | 5 | 2017 | 1940 | 0.380 |
Why?
|
| Nuclear Proteins | 8 | 2020 | 5853 | 0.380 |
Why?
|
| Indans | 3 | 2022 | 96 | 0.380 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 5 | 2012 | 76 | 0.380 |
Why?
|
| Cell Transformation, Neoplastic | 12 | 2021 | 2942 | 0.370 |
Why?
|
| DNA-Binding Proteins | 20 | 2021 | 9647 | 0.350 |
Why?
|
| Cell Lineage | 3 | 2013 | 2504 | 0.340 |
Why?
|
| Immunoenzyme Techniques | 7 | 2015 | 1799 | 0.340 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2010 | 143 | 0.340 |
Why?
|
| von Hippel-Lindau Disease | 2 | 2009 | 152 | 0.330 |
Why?
|
| Animals | 88 | 2024 | 168788 | 0.330 |
Why?
|
| Receptors, KIR | 2 | 2020 | 113 | 0.330 |
Why?
|
| Sulfones | 3 | 2022 | 437 | 0.330 |
Why?
|
| Pyrimidines | 7 | 2022 | 2940 | 0.320 |
Why?
|
| Male | 102 | 2022 | 350027 | 0.320 |
Why?
|
| Histone Demethylases | 6 | 2023 | 321 | 0.320 |
Why?
|
| CD8-Positive T-Lymphocytes | 7 | 2022 | 4477 | 0.320 |
Why?
|
| Mammary Neoplasms, Experimental | 5 | 2012 | 520 | 0.310 |
Why?
|
| Signal Transduction | 26 | 2021 | 23404 | 0.290 |
Why?
|
| Neoplasm Staging | 11 | 2021 | 11007 | 0.290 |
Why?
|
| Cell Differentiation | 10 | 2019 | 11478 | 0.280 |
Why?
|
| Urothelium | 3 | 2016 | 277 | 0.280 |
Why?
|
| Adenoma | 3 | 2015 | 2174 | 0.280 |
Why?
|
| Pyrroles | 6 | 2017 | 1143 | 0.270 |
Why?
|
| Female | 88 | 2022 | 380197 | 0.270 |
Why?
|
| T-Lymphocytes | 6 | 2024 | 10182 | 0.270 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2015 | 2041 | 0.270 |
Why?
|
| Immunotherapy | 9 | 2021 | 4440 | 0.260 |
Why?
|
| Androgens | 5 | 2013 | 1279 | 0.260 |
Why?
|
| Retinoblastoma Protein | 3 | 2018 | 704 | 0.260 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2008 | 369 | 0.250 |
Why?
|
| Cell Cycle Proteins | 7 | 2012 | 3461 | 0.250 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 4 | 2016 | 664 | 0.250 |
Why?
|
| Lipogenesis | 2 | 2018 | 212 | 0.240 |
Why?
|
| Disease Models, Animal | 14 | 2021 | 18027 | 0.240 |
Why?
|
| Phosphatidylinositol 3-Kinases | 7 | 2022 | 2938 | 0.240 |
Why?
|
| Indoles | 6 | 2017 | 1838 | 0.240 |
Why?
|
| Epithelial Cells | 10 | 2009 | 3690 | 0.240 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2013 | 1372 | 0.240 |
Why?
|
| Membrane Proteins | 5 | 2014 | 7879 | 0.230 |
Why?
|
| Molecular Targeted Therapy | 8 | 2019 | 2727 | 0.230 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2021 | 6535 | 0.230 |
Why?
|
| Nephrectomy | 4 | 2019 | 1049 | 0.230 |
Why?
|
| Aged | 46 | 2021 | 163253 | 0.230 |
Why?
|
| Ubiquitin-Protein Ligases | 4 | 2018 | 1860 | 0.230 |
Why?
|
| Sirolimus | 6 | 2018 | 1563 | 0.220 |
Why?
|
| Adenocarcinoma | 10 | 2022 | 6352 | 0.220 |
Why?
|
| Butyrate Response Factor 1 | 1 | 2022 | 10 | 0.220 |
Why?
|
| Indazoles | 5 | 2017 | 287 | 0.220 |
Why?
|
| Mice, Nude | 13 | 2019 | 3689 | 0.220 |
Why?
|
| Tumor Microenvironment | 8 | 2023 | 3584 | 0.220 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2018 | 5169 | 0.220 |
Why?
|
| Tankyrases | 1 | 2022 | 14 | 0.220 |
Why?
|
| Survival Analysis | 9 | 2021 | 10250 | 0.210 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2019 | 840 | 0.210 |
Why?
|
| Middle Aged | 48 | 2021 | 213367 | 0.210 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2022 | 933 | 0.210 |
Why?
|
| Carcinoma | 4 | 2023 | 2375 | 0.210 |
Why?
|
| Survival Rate | 9 | 2020 | 12781 | 0.210 |
Why?
|
| DNA, Neoplasm | 4 | 2016 | 1758 | 0.210 |
Why?
|
| Xenograft Model Antitumor Assays | 11 | 2019 | 3557 | 0.200 |
Why?
|
| Vascular Endothelial Growth Factor A | 8 | 2023 | 3506 | 0.200 |
Why?
|
| Loss of Heterozygosity | 2 | 2021 | 684 | 0.200 |
Why?
|
| Apoptosis | 13 | 2019 | 9728 | 0.200 |
Why?
|
| Receptor, Notch2 | 1 | 2021 | 89 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-akt | 8 | 2016 | 2503 | 0.200 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 2 | 2022 | 315 | 0.190 |
Why?
|
| Core Binding Factor Alpha 1 Subunit | 1 | 2021 | 164 | 0.190 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 4 | 2021 | 704 | 0.190 |
Why?
|
| Treatment Outcome | 23 | 2022 | 63119 | 0.190 |
Why?
|
| Immunoglobulins | 2 | 2023 | 881 | 0.190 |
Why?
|
| Polymerase Chain Reaction | 8 | 2013 | 6172 | 0.190 |
Why?
|
| AMP-Activated Protein Kinases | 3 | 2014 | 608 | 0.190 |
Why?
|
| Doxorubicin | 5 | 2014 | 2220 | 0.190 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2017 | 9230 | 0.190 |
Why?
|
| Immune System Diseases | 1 | 2023 | 263 | 0.190 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2014 | 424 | 0.190 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 3 | 2000 | 335 | 0.190 |
Why?
|
| Catheter Ablation | 7 | 2011 | 2758 | 0.190 |
Why?
|
| Aged, 80 and over | 18 | 2020 | 57768 | 0.190 |
Why?
|
| Neoplasms | 11 | 2020 | 21672 | 0.190 |
Why?
|
| Sarcoma | 3 | 2023 | 1897 | 0.180 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 2 | 2000 | 342 | 0.180 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 2 | 2019 | 182 | 0.180 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 7 | 2008 | 323 | 0.180 |
Why?
|
| Retinoblastoma-Binding Protein 2 | 1 | 2019 | 31 | 0.180 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2022 | 251 | 0.180 |
Why?
|
| Epithelium | 3 | 2015 | 1680 | 0.180 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 1999 | 92 | 0.180 |
Why?
|
| Amino Acid Transport System y+ | 2 | 2016 | 35 | 0.170 |
Why?
|
| 5'-Nucleotidase | 1 | 2020 | 160 | 0.170 |
Why?
|
| Genome, Human | 5 | 2018 | 4420 | 0.170 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2020 | 546 | 0.170 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2022 | 1581 | 0.170 |
Why?
|
| Lung Neoplasms | 6 | 2023 | 13096 | 0.170 |
Why?
|
| Neovascularization, Pathologic | 5 | 2016 | 2636 | 0.170 |
Why?
|
| Aspartic Acid | 1 | 2002 | 576 | 0.170 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2013 | 4033 | 0.170 |
Why?
|
| Neuroendocrine Cells | 1 | 2019 | 61 | 0.170 |
Why?
|
| Genes, Immunoglobulin | 1 | 1999 | 291 | 0.170 |
Why?
|
| Rhabdoid Tumor | 1 | 2021 | 212 | 0.170 |
Why?
|
| Disease-Free Survival | 8 | 2017 | 6893 | 0.170 |
Why?
|
| Serine Proteases | 1 | 2018 | 52 | 0.160 |
Why?
|
| Receptor, Notch1 | 1 | 2021 | 502 | 0.160 |
Why?
|
| Lymphoma, B-Cell | 3 | 2000 | 931 | 0.160 |
Why?
|
| STAT3 Transcription Factor | 2 | 2015 | 874 | 0.160 |
Why?
|
| Ubiquitination | 2 | 2014 | 1011 | 0.160 |
Why?
|
| DNA Copy Number Variations | 4 | 2023 | 1940 | 0.160 |
Why?
|
| Cell Cycle | 6 | 2014 | 2967 | 0.160 |
Why?
|
| Triazines | 1 | 2020 | 316 | 0.160 |
Why?
|
| Sterol Regulatory Element Binding Proteins | 1 | 2018 | 27 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2019 | 535 | 0.160 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2018 | 97 | 0.160 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2019 | 628 | 0.160 |
Why?
|
| RNA, Neoplasm | 3 | 2015 | 769 | 0.160 |
Why?
|
| Oncogenes | 4 | 2023 | 1265 | 0.160 |
Why?
|
| DNA Mutational Analysis | 3 | 2013 | 4188 | 0.160 |
Why?
|
| Glutathione Peroxidase | 1 | 2019 | 255 | 0.150 |
Why?
|
| Foot Diseases | 1 | 1999 | 143 | 0.150 |
Why?
|
| Phenotype | 14 | 2023 | 16365 | 0.150 |
Why?
|
| Phosphorylation | 9 | 2016 | 8437 | 0.150 |
Why?
|
| Gene Rearrangement | 5 | 2011 | 1179 | 0.150 |
Why?
|
| Kidney | 7 | 2019 | 7183 | 0.150 |
Why?
|
| Adult | 32 | 2020 | 214035 | 0.150 |
Why?
|
| Chromatin | 3 | 2023 | 2934 | 0.150 |
Why?
|
| Breast Neoplasms | 9 | 2022 | 20817 | 0.150 |
Why?
|
| Histone Code | 1 | 2018 | 163 | 0.150 |
Why?
|
| Liposomes | 2 | 2011 | 758 | 0.150 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2019 | 3474 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2019 | 322 | 0.150 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2023 | 1363 | 0.140 |
Why?
|
| Nevus, Pigmented | 1 | 1999 | 219 | 0.140 |
Why?
|
| Protein Kinases | 4 | 2015 | 1639 | 0.140 |
Why?
|
| Receptor, erbB-2 | 3 | 2012 | 2416 | 0.140 |
Why?
|
| Histone-Lysine N-Methyltransferase | 3 | 2020 | 671 | 0.140 |
Why?
|
| Receptors, Estrogen | 2 | 2002 | 2186 | 0.140 |
Why?
|
| Genomics | 8 | 2022 | 5722 | 0.140 |
Why?
|
| Metabolic Networks and Pathways | 3 | 2018 | 782 | 0.140 |
Why?
|
| Eccrine Glands | 1 | 1996 | 45 | 0.140 |
Why?
|
| Cytosine Deaminase | 1 | 2016 | 68 | 0.140 |
Why?
|
| Colorectal Neoplasms | 2 | 2013 | 6773 | 0.140 |
Why?
|
| Spin Labels | 3 | 2016 | 332 | 0.140 |
Why?
|
| Microsatellite Repeats | 1 | 2018 | 802 | 0.140 |
Why?
|
| High-Throughput Nucleotide Sequencing | 9 | 2021 | 3598 | 0.130 |
Why?
|
| Complementarity Determining Regions | 1 | 2016 | 149 | 0.130 |
Why?
|
| HMGB1 Protein | 1 | 2017 | 133 | 0.130 |
Why?
|
| Activin Receptors, Type II | 1 | 2016 | 127 | 0.130 |
Why?
|
| Mice, Transgenic | 10 | 2013 | 9735 | 0.130 |
Why?
|
| NF-E2-Related Factor 2 | 2 | 2015 | 377 | 0.130 |
Why?
|
| Mice, Knockout | 11 | 2021 | 14556 | 0.130 |
Why?
|
| Neoplasms, Second Primary | 2 | 2017 | 1061 | 0.130 |
Why?
|
| Cell Membrane | 2 | 2015 | 3748 | 0.130 |
Why?
|
| Brain Neoplasms | 3 | 2023 | 8860 | 0.130 |
Why?
|
| Follow-Up Studies | 8 | 2022 | 39045 | 0.130 |
Why?
|
| Enzyme Inhibitors | 6 | 2022 | 3800 | 0.130 |
Why?
|
| Lymphocyte Subsets | 1 | 2016 | 315 | 0.130 |
Why?
|
| Neoplasm Transplantation | 7 | 2014 | 2085 | 0.130 |
Why?
|
| Disease Progression | 11 | 2018 | 13280 | 0.130 |
Why?
|
| Metaplasia | 2 | 2013 | 313 | 0.130 |
Why?
|
| Skin Neoplasms | 5 | 2004 | 5670 | 0.130 |
Why?
|
| Receptors, Notch | 1 | 2019 | 739 | 0.130 |
Why?
|
| BRCA1 Protein | 1 | 2021 | 1149 | 0.130 |
Why?
|
| Chemokine CXCL12 | 1 | 2017 | 464 | 0.130 |
Why?
|
| Paracrine Communication | 1 | 2016 | 276 | 0.120 |
Why?
|
| Angiomyolipoma | 1 | 2016 | 190 | 0.120 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 2 | 2015 | 437 | 0.120 |
Why?
|
| Proline | 1 | 2016 | 458 | 0.120 |
Why?
|
| Deoxycytidine | 2 | 2017 | 825 | 0.120 |
Why?
|
| Paraffin Embedding | 3 | 2008 | 299 | 0.120 |
Why?
|
| src-Family Kinases | 2 | 2014 | 551 | 0.120 |
Why?
|
| Elafin | 1 | 2014 | 33 | 0.120 |
Why?
|
| G-Protein-Coupled Receptor Kinase 3 | 1 | 2014 | 7 | 0.120 |
Why?
|
| Imidazoles | 4 | 2017 | 1206 | 0.120 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2014 | 67 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 4 | 2015 | 9275 | 0.120 |
Why?
|
| Pyrazines | 1 | 2020 | 1231 | 0.120 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2014 | 105 | 0.120 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 1677 | 0.120 |
Why?
|
| Androgen Receptor Antagonists | 2 | 2012 | 114 | 0.120 |
Why?
|
| Lymphangioleiomyomatosis | 1 | 2016 | 210 | 0.120 |
Why?
|
| Enzyme Activators | 1 | 2014 | 57 | 0.120 |
Why?
|
| Leukemia | 1 | 2022 | 1508 | 0.120 |
Why?
|
| Fas Ligand Protein | 1 | 2014 | 217 | 0.120 |
Why?
|
| Cytological Techniques | 1 | 2015 | 219 | 0.120 |
Why?
|
| Immunity | 2 | 2018 | 1012 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2015 | 318 | 0.120 |
Why?
|
| GRB10 Adaptor Protein | 1 | 2013 | 22 | 0.120 |
Why?
|
| Protein Isoforms | 3 | 2014 | 1731 | 0.120 |
Why?
|
| Hand | 1 | 1999 | 884 | 0.110 |
Why?
|
| Myeloid Cells | 3 | 2023 | 809 | 0.110 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2013 | 78 | 0.110 |
Why?
|
| Hypoxia-Inducible Factor 1 | 2 | 2019 | 198 | 0.110 |
Why?
|
| Models, Biological | 9 | 2016 | 9582 | 0.110 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2013 | 124 | 0.110 |
Why?
|
| Receptors, IgG | 1 | 2016 | 582 | 0.110 |
Why?
|
| Protective Agents | 1 | 2014 | 156 | 0.110 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2013 | 2915 | 0.110 |
Why?
|
| Clinical Protocols | 1 | 2019 | 1462 | 0.110 |
Why?
|
| Translocation, Genetic | 1 | 2018 | 1420 | 0.110 |
Why?
|
| Cyclin D | 1 | 2012 | 71 | 0.110 |
Why?
|
| Cystectomy | 2 | 2017 | 686 | 0.110 |
Why?
|
| Pituitary Neoplasms | 2 | 2018 | 1346 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2021 | 9960 | 0.110 |
Why?
|
| Retrospective Studies | 10 | 2022 | 77426 | 0.110 |
Why?
|
| Sphingosine | 1 | 2015 | 307 | 0.110 |
Why?
|
| Genotype | 7 | 2018 | 12956 | 0.110 |
Why?
|
| Brain Injuries | 2 | 2002 | 2025 | 0.110 |
Why?
|
| SOX9 Transcription Factor | 1 | 2013 | 146 | 0.110 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2018 | 770 | 0.110 |
Why?
|
| Lysophospholipids | 1 | 2015 | 331 | 0.110 |
Why?
|
| Proto-Oncogene Proteins | 5 | 2011 | 4553 | 0.110 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2014 | 441 | 0.100 |
Why?
|
| Therapies, Investigational | 1 | 2013 | 112 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2013 | 403 | 0.100 |
Why?
|
| Citric Acid Cycle | 1 | 2013 | 232 | 0.100 |
Why?
|
| Odds Ratio | 3 | 2019 | 9849 | 0.100 |
Why?
|
| Comparative Genomic Hybridization | 2 | 2014 | 496 | 0.100 |
Why?
|
| Carcinoma in Situ | 2 | 2017 | 805 | 0.100 |
Why?
|
| Cyclins | 1 | 2014 | 603 | 0.100 |
Why?
|
| Retinol-Binding Proteins, Cellular | 1 | 2011 | 13 | 0.100 |
Why?
|
| Protein Structure, Tertiary | 3 | 2015 | 3846 | 0.100 |
Why?
|
| Qb-SNARE Proteins | 1 | 2011 | 36 | 0.100 |
Why?
|
| Receptors, Androgen | 4 | 2006 | 1057 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 4 | 2018 | 4803 | 0.100 |
Why?
|
| Cytodiagnosis | 1 | 2015 | 435 | 0.100 |
Why?
|
| Gene Knock-In Techniques | 1 | 2013 | 418 | 0.100 |
Why?
|
| Microtubule-Associated Proteins | 4 | 2001 | 1086 | 0.100 |
Why?
|
| Cohort Studies | 8 | 2020 | 40559 | 0.100 |
Why?
|
| Immunologic Factors | 1 | 2021 | 1582 | 0.100 |
Why?
|
| Cytoplasm | 3 | 2014 | 1539 | 0.100 |
Why?
|
| Cysteine | 1 | 2016 | 874 | 0.100 |
Why?
|
| HSP70 Heat-Shock Proteins | 2 | 2011 | 404 | 0.100 |
Why?
|
| Esophageal Neoplasms | 1 | 2021 | 1582 | 0.100 |
Why?
|
| Perioperative Care | 1 | 2019 | 1000 | 0.100 |
Why?
|
| Forkhead Transcription Factors | 3 | 2023 | 1613 | 0.100 |
Why?
|
| Cisplatin | 2 | 2014 | 1642 | 0.100 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2000 | 2455 | 0.100 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2014 | 648 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 6 | 2014 | 3614 | 0.100 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2011 | 154 | 0.100 |
Why?
|
| Cullin Proteins | 1 | 2012 | 180 | 0.100 |
Why?
|
| Androgen Antagonists | 3 | 2022 | 1361 | 0.100 |
Why?
|
| Genes, Neoplasm | 1 | 2013 | 376 | 0.100 |
Why?
|
| Metabolomics | 1 | 2019 | 1483 | 0.100 |
Why?
|
| Transplantation, Heterologous | 4 | 2012 | 2382 | 0.100 |
Why?
|
| Histocytochemistry | 3 | 2011 | 719 | 0.090 |
Why?
|
| Colonic Neoplasms | 1 | 2022 | 2538 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2011 | 300 | 0.090 |
Why?
|
| Mice, Inbred NOD | 2 | 2014 | 1877 | 0.090 |
Why?
|
| Biopsy | 3 | 2019 | 6757 | 0.090 |
Why?
|
| Myocardial Stunning | 1 | 2010 | 68 | 0.090 |
Why?
|
| Epigenomics | 3 | 2023 | 903 | 0.090 |
Why?
|
| Quercetin | 1 | 2011 | 93 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 6 | 2018 | 6313 | 0.090 |
Why?
|
| Procollagen-Proline Dioxygenase | 1 | 2010 | 86 | 0.090 |
Why?
|
| F-Box Proteins | 1 | 2012 | 197 | 0.090 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2011 | 258 | 0.090 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2012 | 503 | 0.090 |
Why?
|
| Smad4 Protein | 1 | 2011 | 163 | 0.090 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2024 | 2988 | 0.090 |
Why?
|
| HEK293 Cells | 5 | 2019 | 4201 | 0.090 |
Why?
|
| Cyclooxygenase 2 | 1 | 2013 | 611 | 0.090 |
Why?
|
| Polyomavirus | 1 | 2011 | 248 | 0.090 |
Why?
|
| Neoplasms, Experimental | 2 | 2006 | 1275 | 0.090 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2016 | 2737 | 0.090 |
Why?
|
| Neoadjuvant Therapy | 3 | 2019 | 2726 | 0.090 |
Why?
|
| Myristic Acids | 1 | 2009 | 48 | 0.090 |
Why?
|
| Mice, SCID | 2 | 2014 | 2716 | 0.090 |
Why?
|
| Rats, Inbred F344 | 5 | 2010 | 862 | 0.090 |
Why?
|
| Genetic Heterogeneity | 3 | 2018 | 733 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2011 | 220 | 0.090 |
Why?
|
| Antineoplastic Protocols | 1 | 2009 | 50 | 0.090 |
Why?
|
| Gene Deletion | 5 | 2020 | 2751 | 0.090 |
Why?
|
| Quinolines | 2 | 2012 | 730 | 0.080 |
Why?
|
| Oxygen | 2 | 2019 | 4187 | 0.080 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2013 | 635 | 0.080 |
Why?
|
| Leiomyomatosis | 1 | 2009 | 70 | 0.080 |
Why?
|
| Computational Biology | 1 | 2021 | 3523 | 0.080 |
Why?
|
| STAT5 Transcription Factor | 1 | 2009 | 259 | 0.080 |
Why?
|
| Aminopyridines | 3 | 2019 | 542 | 0.080 |
Why?
|
| Brain Edema | 2 | 2006 | 617 | 0.080 |
Why?
|
| Down-Regulation | 4 | 2015 | 3001 | 0.080 |
Why?
|
| Gene Expression | 2 | 2019 | 7799 | 0.080 |
Why?
|
| Oncogene Protein p21(ras) | 2 | 2014 | 82 | 0.080 |
Why?
|
| Immunophenotyping | 2 | 2011 | 1880 | 0.080 |
Why?
|
| Enzyme Activation | 5 | 2018 | 3701 | 0.080 |
Why?
|
| Pyrazoles | 2 | 2022 | 1973 | 0.080 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 1838 | 0.080 |
Why?
|
| Cell Hypoxia | 3 | 2019 | 675 | 0.080 |
Why?
|
| RNA, Messenger | 8 | 2016 | 13036 | 0.080 |
Why?
|
| Up-Regulation | 5 | 2016 | 4217 | 0.080 |
Why?
|
| Skin Diseases | 1 | 1996 | 1065 | 0.080 |
Why?
|
| Tissue Banks | 1 | 2008 | 184 | 0.080 |
Why?
|
| Glioma | 1 | 2022 | 3401 | 0.070 |
Why?
|
| Virulence Factors | 1 | 2011 | 509 | 0.070 |
Why?
|
| Genetic Association Studies | 2 | 2016 | 2702 | 0.070 |
Why?
|
| DNA Damage | 2 | 2015 | 2432 | 0.070 |
Why?
|
| Lymphocytes | 1 | 2015 | 2617 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2012 | 1284 | 0.070 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2016 | 2540 | 0.070 |
Why?
|
| Keratin-15 | 1 | 2006 | 22 | 0.070 |
Why?
|
| Lymphoma, T-Cell | 2 | 2000 | 299 | 0.070 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2016 | 2649 | 0.070 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2014 | 1660 | 0.070 |
Why?
|
| Cell Adhesion Molecules | 1 | 2013 | 1602 | 0.070 |
Why?
|
| Prostatic Diseases | 1 | 2006 | 56 | 0.070 |
Why?
|
| Combined Modality Therapy | 7 | 2019 | 8628 | 0.070 |
Why?
|
| Intestinal Polyps | 2 | 2005 | 99 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 3 | 2015 | 5867 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2022 | 3311 | 0.070 |
Why?
|
| beta-Galactosidase | 2 | 2005 | 573 | 0.070 |
Why?
|
| Repressor Proteins | 2 | 2022 | 3023 | 0.070 |
Why?
|
| Paclitaxel | 2 | 2010 | 1707 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2016 | 15525 | 0.070 |
Why?
|
| Arsenicals | 1 | 2006 | 124 | 0.070 |
Why?
|
| Rats | 11 | 2013 | 24273 | 0.070 |
Why?
|
| Cell Survival | 3 | 2014 | 5881 | 0.070 |
Why?
|
| Gene Silencing | 2 | 2009 | 1538 | 0.070 |
Why?
|
| DNA Methylation | 3 | 2015 | 4289 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2021 | 987 | 0.070 |
Why?
|
| Quality Control | 1 | 2008 | 843 | 0.070 |
Why?
|
| Melanoma | 2 | 2019 | 5475 | 0.060 |
Why?
|
| Sarcoma, Experimental | 1 | 2005 | 128 | 0.060 |
Why?
|
| Ki-67 Antigen | 4 | 2016 | 644 | 0.060 |
Why?
|
| Genetic Variation | 3 | 2016 | 6546 | 0.060 |
Why?
|
| Lymphocyte Count | 2 | 2019 | 793 | 0.060 |
Why?
|
| Clinical Trials as Topic | 4 | 2021 | 7908 | 0.060 |
Why?
|
| Sequence Analysis, RNA | 3 | 2020 | 2013 | 0.060 |
Why?
|
| Tumor Burden | 3 | 2016 | 1914 | 0.060 |
Why?
|
| Arginase | 1 | 2005 | 79 | 0.060 |
Why?
|
| Growth Inhibitors | 1 | 2006 | 385 | 0.060 |
Why?
|
| Epidemiologic Methods | 1 | 2010 | 1365 | 0.060 |
Why?
|
| Thyroid Neoplasms | 1 | 2018 | 2281 | 0.060 |
Why?
|
| Gene Expression Regulation | 4 | 2016 | 12075 | 0.060 |
Why?
|
| Bone Marrow Cells | 1 | 2012 | 2513 | 0.060 |
Why?
|
| Oxides | 1 | 2006 | 405 | 0.060 |
Why?
|
| Histones | 4 | 2019 | 2600 | 0.060 |
Why?
|
| Carrier Proteins | 2 | 2012 | 5021 | 0.060 |
Why?
|
| Epigenesis, Genetic | 2 | 2018 | 3646 | 0.060 |
Why?
|
| Transcription, Genetic | 5 | 2021 | 7723 | 0.060 |
Why?
|
| Killer Cells, Natural | 3 | 2020 | 2133 | 0.060 |
Why?
|
| Specimen Handling | 1 | 2009 | 694 | 0.060 |
Why?
|
| In Situ Hybridization | 4 | 2001 | 1950 | 0.060 |
Why?
|
| Retroviridae | 2 | 2008 | 914 | 0.060 |
Why?
|
| Gene Transfer Techniques | 2 | 2002 | 1224 | 0.060 |
Why?
|
| Calcium Channels | 1 | 2008 | 622 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 8 | 2018 | 21824 | 0.060 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2010 | 851 | 0.060 |
Why?
|
| Time Factors | 6 | 2017 | 40063 | 0.060 |
Why?
|
| Trauma Severity Indices | 1 | 2006 | 481 | 0.060 |
Why?
|
| Cell Line | 5 | 2019 | 15999 | 0.060 |
Why?
|
| Reference Values | 2 | 2002 | 4982 | 0.060 |
Why?
|
| Cyclin-Dependent Kinases | 4 | 2001 | 671 | 0.060 |
Why?
|
| Morpholines | 3 | 2016 | 573 | 0.060 |
Why?
|
| Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 2 | 2000 | 43 | 0.060 |
Why?
|
| Epidermal Growth Factor | 2 | 2008 | 709 | 0.060 |
Why?
|
| Blotting, Western | 7 | 2010 | 5180 | 0.060 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2006 | 414 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2012 | 15070 | 0.060 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2008 | 871 | 0.060 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2005 | 473 | 0.060 |
Why?
|
| Salicylanilides | 1 | 2022 | 15 | 0.060 |
Why?
|
| MicroRNAs | 3 | 2015 | 3747 | 0.060 |
Why?
|
| Prospective Studies | 8 | 2022 | 53280 | 0.050 |
Why?
|
| Methylation | 2 | 2019 | 1108 | 0.050 |
Why?
|
| Peutz-Jeghers Syndrome | 1 | 2002 | 50 | 0.050 |
Why?
|
| Transplantation Chimera | 1 | 2005 | 612 | 0.050 |
Why?
|
| Gene Knockdown Techniques | 3 | 2013 | 1655 | 0.050 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2002 | 90 | 0.050 |
Why?
|
| Keratinocytes | 1 | 2006 | 798 | 0.050 |
Why?
|
| Genes, p53 | 2 | 2002 | 755 | 0.050 |
Why?
|
| Chromosomal Instability | 1 | 2023 | 184 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2018 | 3772 | 0.050 |
Why?
|
| Antibodies | 2 | 2024 | 2461 | 0.050 |
Why?
|
| Neurochemistry | 1 | 2002 | 29 | 0.050 |
Why?
|
| Orchiectomy | 3 | 2013 | 466 | 0.050 |
Why?
|
| Antigens, CD | 1 | 2013 | 4026 | 0.050 |
Why?
|
| 4-Nitroquinoline-1-oxide | 1 | 2021 | 20 | 0.050 |
Why?
|
| Gene Frequency | 1 | 2009 | 3588 | 0.050 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2002 | 90 | 0.050 |
Why?
|
| Transfection | 4 | 2021 | 5892 | 0.050 |
Why?
|
| Dissection | 2 | 2002 | 295 | 0.050 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2020 | 890 | 0.050 |
Why?
|
| Gene Amplification | 2 | 2010 | 1062 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2014 | 3385 | 0.050 |
Why?
|
| Phenylthiohydantoin | 2 | 2013 | 192 | 0.050 |
Why?
|
| Blood Platelets | 1 | 2012 | 2508 | 0.050 |
Why?
|
| Myocytes, Cardiac | 1 | 2010 | 1637 | 0.050 |
Why?
|
| Carcinoma, Embryonal | 1 | 2001 | 38 | 0.050 |
Why?
|
| Craniocerebral Trauma | 1 | 2006 | 482 | 0.050 |
Why?
|
| Neutrophils | 3 | 2019 | 3717 | 0.050 |
Why?
|
| Benzoxazoles | 1 | 2022 | 77 | 0.050 |
Why?
|
| Cystadenoma, Serous | 1 | 2002 | 102 | 0.050 |
Why?
|
| Benzimidazoles | 2 | 2019 | 851 | 0.050 |
Why?
|
| Germ-Line Mutation | 2 | 2021 | 1787 | 0.050 |
Why?
|
| Species Specificity | 2 | 2019 | 2480 | 0.050 |
Why?
|
| Angiotensin I | 1 | 2021 | 56 | 0.050 |
Why?
|
| Recombinant Proteins | 3 | 2016 | 6612 | 0.050 |
Why?
|
| Biopsy, Needle | 2 | 2018 | 1640 | 0.050 |
Why?
|
| Conserved Sequence | 2 | 2015 | 1202 | 0.050 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2005 | 601 | 0.050 |
Why?
|
| Drug Administration Schedule | 3 | 2014 | 4929 | 0.050 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2005 | 484 | 0.050 |
Why?
|
| Cell Death | 2 | 2010 | 1708 | 0.050 |
Why?
|
| Cyclin D1 | 2 | 2014 | 462 | 0.050 |
Why?
|
| Disease Susceptibility | 2 | 2019 | 1782 | 0.050 |
Why?
|
| cdc25 Phosphatases | 1 | 2000 | 62 | 0.050 |
Why?
|
| Isoenzymes | 3 | 2014 | 1726 | 0.050 |
Why?
|
| Insulin | 2 | 2008 | 6583 | 0.050 |
Why?
|
| Young Adult | 5 | 2020 | 56436 | 0.050 |
Why?
|
| Estrogen Receptor beta | 1 | 2001 | 175 | 0.050 |
Why?
|
| CDC2-CDC28 Kinases | 1 | 2000 | 113 | 0.050 |
Why?
|
| Pseudolymphoma | 1 | 2000 | 30 | 0.050 |
Why?
|
| Vinblastine | 2 | 2014 | 490 | 0.050 |
Why?
|
| Endopeptidases | 1 | 2004 | 772 | 0.050 |
Why?
|
| Cell Division | 3 | 2002 | 4567 | 0.050 |
Why?
|
| Cell Adhesion | 2 | 2008 | 3144 | 0.050 |
Why?
|
| Blood Coagulation | 1 | 2006 | 1127 | 0.050 |
Why?
|
| Benzamides | 3 | 2013 | 1378 | 0.050 |
Why?
|
| Choline | 1 | 2002 | 493 | 0.050 |
Why?
|
| Seminoma | 1 | 2001 | 136 | 0.040 |
Why?
|
| Herpesvirus 8, Human | 2 | 2001 | 258 | 0.040 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2008 | 1018 | 0.040 |
Why?
|
| Aneuploidy | 1 | 2023 | 530 | 0.040 |
Why?
|
| Fibroblasts | 4 | 2018 | 4156 | 0.040 |
Why?
|
| Retreatment | 1 | 2021 | 610 | 0.040 |
Why?
|
| Microvessels | 2 | 2015 | 544 | 0.040 |
Why?
|
| GPI-Linked Proteins | 1 | 2020 | 434 | 0.040 |
Why?
|
| Cell Nucleus | 4 | 2000 | 2969 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2020 | 2505 | 0.040 |
Why?
|
| Macrophages | 3 | 2021 | 5657 | 0.040 |
Why?
|
| Genome-Wide Association Study | 3 | 2018 | 12264 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2015 | 17449 | 0.040 |
Why?
|
| Kynurenine | 1 | 2019 | 138 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2020 | 380 | 0.040 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2021 | 365 | 0.040 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1999 | 212 | 0.040 |
Why?
|
| Lymphocytosis | 1 | 1999 | 119 | 0.040 |
Why?
|
| Staining and Labeling | 2 | 2015 | 1100 | 0.040 |
Why?
|
| Heterozygote | 2 | 2021 | 2805 | 0.040 |
Why?
|
| Gene Fusion | 1 | 2022 | 371 | 0.040 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2000 | 431 | 0.040 |
Why?
|
| Risk Factors | 8 | 2022 | 72280 | 0.040 |
Why?
|
| Water-Electrolyte Balance | 1 | 2000 | 346 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2022 | 552 | 0.040 |
Why?
|
| Mycosis Fungoides | 1 | 2000 | 163 | 0.040 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2000 | 434 | 0.040 |
Why?
|
| Proteins | 2 | 2010 | 6101 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2006 | 4752 | 0.040 |
Why?
|
| Molecular Sequence Data | 3 | 2014 | 18116 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2009 | 3921 | 0.040 |
Why?
|
| DNA Primers | 2 | 2000 | 2892 | 0.040 |
Why?
|
| B-Lymphocyte Subsets | 1 | 1999 | 246 | 0.040 |
Why?
|
| Chromosome Aberrations | 2 | 2015 | 1814 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2020 | 537 | 0.040 |
Why?
|
| Ligands | 2 | 2016 | 3294 | 0.040 |
Why?
|
| Lipid Peroxidation | 1 | 2019 | 270 | 0.040 |
Why?
|
| Alleles | 3 | 2018 | 6938 | 0.040 |
Why?
|
| Cluster Analysis | 2 | 2015 | 2715 | 0.040 |
Why?
|
| Genes, Retinoblastoma | 1 | 2018 | 136 | 0.040 |
Why?
|
| Mice, Inbred Strains | 1 | 2000 | 1827 | 0.040 |
Why?
|
| Nitriles | 2 | 2013 | 952 | 0.040 |
Why?
|
| Mice, Mutant Strains | 3 | 2010 | 1866 | 0.040 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2020 | 1337 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2009 | 2218 | 0.040 |
Why?
|
| Angiotensin II | 1 | 2021 | 881 | 0.040 |
Why?
|
| Diagnosis, Differential | 6 | 2015 | 12961 | 0.040 |
Why?
|
| Tryptophan | 1 | 2019 | 479 | 0.040 |
Why?
|
| Administration, Intravesical | 1 | 2017 | 91 | 0.040 |
Why?
|
| Chromosome Segregation | 1 | 2018 | 236 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2016 | 10949 | 0.040 |
Why?
|
| Protein Binding | 3 | 2015 | 9392 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2010 | 1434 | 0.040 |
Why?
|
| Aryl Hydrocarbon Receptor Nuclear Translocator | 1 | 2017 | 38 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2014 | 35423 | 0.040 |
Why?
|
| Jurkat Cells | 1 | 1999 | 743 | 0.040 |
Why?
|
| Heart Septal Defects | 1 | 2018 | 192 | 0.040 |
Why?
|
| Melanins | 1 | 1999 | 289 | 0.040 |
Why?
|
| Transcriptional Activation | 3 | 2010 | 1782 | 0.040 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2022 | 871 | 0.040 |
Why?
|
| Testosterone | 2 | 2012 | 2411 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2008 | 3769 | 0.040 |
Why?
|
| RNA Interference | 2 | 2019 | 2890 | 0.040 |
Why?
|
| Hydroxylation | 1 | 2016 | 141 | 0.040 |
Why?
|
| Triazoles | 1 | 2022 | 911 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2020 | 1590 | 0.040 |
Why?
|
| Cytoskeletal Proteins | 1 | 2002 | 1364 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 2023 | 1275 | 0.030 |
Why?
|
| Creatinine | 1 | 2002 | 1919 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 2 | 2020 | 6386 | 0.030 |
Why?
|
| Clone Cells | 1 | 1999 | 1692 | 0.030 |
Why?
|
| Benzylamines | 1 | 2017 | 226 | 0.030 |
Why?
|
| Glucose | 1 | 2008 | 4396 | 0.030 |
Why?
|
| Tissue Embedding | 1 | 2015 | 43 | 0.030 |
Why?
|
| Analysis of Variance | 3 | 2010 | 6367 | 0.030 |
Why?
|
| Erythema | 1 | 1997 | 257 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2019 | 809 | 0.030 |
Why?
|
| Heterocyclic Compounds | 1 | 2017 | 249 | 0.030 |
Why?
|
| Binding Sites | 2 | 2015 | 6116 | 0.030 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2016 | 162 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2020 | 1475 | 0.030 |
Why?
|
| Perfusion | 2 | 2011 | 1359 | 0.030 |
Why?
|
| Integrases | 1 | 2018 | 533 | 0.030 |
Why?
|
| Melanocytes | 1 | 1999 | 515 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 2020 | 1401 | 0.030 |
Why?
|
| DNA, Viral | 2 | 2001 | 2226 | 0.030 |
Why?
|
| Monitoring, Intraoperative | 1 | 2002 | 953 | 0.030 |
Why?
|
| HIV Seropositivity | 1 | 2001 | 971 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2002 | 2700 | 0.030 |
Why?
|
| Base Sequence | 2 | 2013 | 12801 | 0.030 |
Why?
|
| Proto-Oncogene Protein c-ets-2 | 1 | 2014 | 16 | 0.030 |
Why?
|
| Granzymes | 1 | 2016 | 271 | 0.030 |
Why?
|
| Chimera | 1 | 2016 | 485 | 0.030 |
Why?
|
| Testicular Neoplasms | 1 | 2001 | 761 | 0.030 |
Why?
|
| Single-Chain Antibodies | 1 | 2015 | 108 | 0.030 |
Why?
|
| Immunity, Innate | 2 | 2017 | 2958 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2009 | 3508 | 0.030 |
Why?
|
| Germ Cells | 1 | 2018 | 631 | 0.030 |
Why?
|
| Lymphatic Metastasis | 2 | 2014 | 2914 | 0.030 |
Why?
|
| DNA Helicases | 1 | 2020 | 861 | 0.030 |
Why?
|
| Transgenes | 1 | 2018 | 1009 | 0.030 |
Why?
|
| Antigen Presentation | 1 | 2020 | 1284 | 0.030 |
Why?
|
| Plasminogen Activator Inhibitor 2 | 1 | 2014 | 20 | 0.030 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2016 | 279 | 0.030 |
Why?
|
| BCG Vaccine | 1 | 2017 | 368 | 0.030 |
Why?
|
| Filgrastim | 1 | 2014 | 133 | 0.030 |
Why?
|
| Cytidine Deaminase | 1 | 2016 | 252 | 0.030 |
Why?
|
| Multigene Family | 2 | 2010 | 1102 | 0.030 |
Why?
|
| Antigens, CD34 | 1 | 2016 | 657 | 0.030 |
Why?
|
| Caspase 8 | 1 | 2014 | 195 | 0.030 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2015 | 305 | 0.030 |
Why?
|
| Multiprotein Complexes | 2 | 2010 | 1119 | 0.030 |
Why?
|
| Adenoviruses, Human | 1 | 1996 | 257 | 0.030 |
Why?
|
| Graft vs Host Disease | 1 | 2006 | 2957 | 0.030 |
Why?
|
| Barrett Esophagus | 1 | 1998 | 494 | 0.030 |
Why?
|
| Amino Acid Sequence | 2 | 2017 | 13817 | 0.030 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2016 | 294 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2014 | 408 | 0.030 |
Why?
|
| Blood-Brain Barrier | 1 | 2000 | 1016 | 0.030 |
Why?
|
| Tamoxifen | 1 | 2018 | 981 | 0.030 |
Why?
|
| Etoposide | 1 | 2015 | 639 | 0.030 |
Why?
|
| Liver | 2 | 2008 | 7472 | 0.030 |
Why?
|
| Genes, Lethal | 1 | 2013 | 242 | 0.030 |
Why?
|
| RNA-Binding Proteins | 1 | 2022 | 1903 | 0.030 |
Why?
|
| Cell Respiration | 1 | 2013 | 200 | 0.030 |
Why?
|
| Pyruvic Acid | 1 | 2014 | 200 | 0.030 |
Why?
|
| Cell Communication | 2 | 2012 | 1621 | 0.030 |
Why?
|
| ROC Curve | 1 | 2021 | 3527 | 0.030 |
Why?
|
| RNA | 3 | 2014 | 2749 | 0.030 |
Why?
|
| Adolescent | 4 | 2018 | 85759 | 0.030 |
Why?
|
| RNA, Small Interfering | 3 | 2009 | 3505 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2014 | 392 | 0.030 |
Why?
|
| Hyperplasia | 1 | 1996 | 1184 | 0.030 |
Why?
|
| Castration | 1 | 2012 | 158 | 0.030 |
Why?
|
| Adaptation, Physiological | 1 | 2019 | 1312 | 0.030 |
Why?
|
| Breast | 1 | 2002 | 1969 | 0.030 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2018 | 736 | 0.030 |
Why?
|
| Immunoglobulin Heavy Chains | 3 | 2001 | 659 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2016 | 805 | 0.030 |
Why?
|
| Piperazines | 2 | 2019 | 2491 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 1996 | 11732 | 0.030 |
Why?
|
| Thrombospondin 1 | 1 | 2014 | 250 | 0.030 |
Why?
|
| beta Catenin | 2 | 2011 | 1059 | 0.030 |
Why?
|
| Research Design | 1 | 2008 | 5987 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2014 | 553 | 0.030 |
Why?
|
| Paraganglioma, Extra-Adrenal | 1 | 2012 | 46 | 0.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1999 | 1380 | 0.030 |
Why?
|
| Immunoblotting | 2 | 2009 | 1682 | 0.030 |
Why?
|
| Lymphoma | 1 | 2001 | 1873 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2009 | 1213 | 0.030 |
Why?
|
| Mesothelioma | 1 | 1998 | 818 | 0.030 |
Why?
|
| Glomus Tumor | 1 | 2012 | 66 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2023 | 2265 | 0.020 |
Why?
|
| Exons | 2 | 2011 | 2439 | 0.020 |
Why?
|
| Mammary Tumor Virus, Mouse | 1 | 2011 | 61 | 0.020 |
Why?
|
| Protein Engineering | 1 | 2015 | 540 | 0.020 |
Why?
|
| Adaptive Immunity | 1 | 2016 | 713 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2014 | 658 | 0.020 |
Why?
|
| Homozygote | 1 | 2016 | 1786 | 0.020 |
Why?
|
| Cyclin E | 1 | 2012 | 172 | 0.020 |
Why?
|
| Keratins | 2 | 2003 | 515 | 0.020 |
Why?
|
| CpG Islands | 1 | 2015 | 1172 | 0.020 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2012 | 261 | 0.020 |
Why?
|
| Endonucleases | 1 | 2014 | 381 | 0.020 |
Why?
|
| Immune System | 1 | 2016 | 805 | 0.020 |
Why?
|
| Genes, ras | 2 | 2004 | 690 | 0.020 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2013 | 320 | 0.020 |
Why?
|
| Urinary Bladder | 1 | 2017 | 1172 | 0.020 |
Why?
|
| Endocytosis | 1 | 2015 | 985 | 0.020 |
Why?
|
| Glutamic Acid | 1 | 2016 | 1169 | 0.020 |
Why?
|
| Iron | 1 | 2019 | 1774 | 0.020 |
Why?
|
| New York | 1 | 2013 | 886 | 0.020 |
Why?
|
| HLA Antigens | 1 | 2016 | 1382 | 0.020 |
Why?
|
| Necrosis | 2 | 2005 | 1643 | 0.020 |
Why?
|
| Drosophila melanogaster | 1 | 2019 | 1708 | 0.020 |
Why?
|
| Myocardium | 2 | 2010 | 4776 | 0.020 |
Why?
|
| Precipitin Tests | 2 | 2001 | 829 | 0.020 |
Why?
|
| Atrophy | 2 | 2006 | 1582 | 0.020 |
Why?
|
| California | 1 | 2014 | 1402 | 0.020 |
Why?
|
| Deoxyguanosine | 1 | 2010 | 84 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2005 | 4935 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 2030 | 0.020 |
Why?
|
| Crosses, Genetic | 1 | 2011 | 791 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2008 | 19227 | 0.020 |
Why?
|
| Subcellular Fractions | 2 | 2002 | 547 | 0.020 |
Why?
|
| S Phase | 2 | 2000 | 423 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2016 | 1782 | 0.020 |
Why?
|
| Osteopontin | 1 | 2011 | 296 | 0.020 |
Why?
|
| Mitochondria | 2 | 2014 | 3520 | 0.020 |
Why?
|
| Penetrance | 1 | 2011 | 381 | 0.020 |
Why?
|
| Rabbits | 2 | 2006 | 4892 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2021 | 8950 | 0.020 |
Why?
|
| Fumarate Hydratase | 1 | 2009 | 47 | 0.020 |
Why?
|
| Aldehydes | 1 | 2010 | 167 | 0.020 |
Why?
|
| Genes, myc | 1 | 2010 | 399 | 0.020 |
Why?
|
| Validation Studies as Topic | 1 | 2009 | 159 | 0.020 |
Why?
|
| Incidence | 2 | 2022 | 20945 | 0.020 |
Why?
|
| Image Enhancement | 1 | 2000 | 2921 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2009 | 193 | 0.020 |
Why?
|
| Bromodeoxyuridine | 1 | 2009 | 322 | 0.020 |
Why?
|
| Proportional Hazards Models | 2 | 2014 | 12355 | 0.020 |
Why?
|
| Cytokines | 1 | 2023 | 7326 | 0.020 |
Why?
|
| Acetylcysteine | 1 | 2010 | 272 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2015 | 1442 | 0.020 |
Why?
|
| Exudates and Transudates | 2 | 1999 | 171 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2014 | 1181 | 0.020 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2012 | 407 | 0.020 |
Why?
|
| bcl-X Protein | 1 | 2010 | 411 | 0.020 |
Why?
|
| B-Lymphocytes | 2 | 2018 | 4665 | 0.020 |
Why?
|
| Sex Factors | 2 | 2014 | 10396 | 0.020 |
Why?
|
| Telomerase | 2 | 2004 | 729 | 0.020 |
Why?
|
| Norway | 1 | 2009 | 448 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2021 | 5096 | 0.020 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 1 | 2008 | 84 | 0.020 |
Why?
|
| Poisson Distribution | 1 | 2009 | 513 | 0.020 |
Why?
|
| Algorithms | 1 | 2008 | 13885 | 0.020 |
Why?
|
| Radiography, Abdominal | 1 | 2011 | 537 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2002 | 14726 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2010 | 759 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2013 | 1701 | 0.020 |
Why?
|
| Methotrexate | 1 | 2014 | 1720 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2013 | 2619 | 0.020 |
Why?
|
| Genetic Engineering | 1 | 2013 | 952 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2017 | 5076 | 0.020 |
Why?
|
| Quality of Life | 2 | 2019 | 12805 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2011 | 2256 | 0.020 |
Why?
|
| Heat-Shock Proteins | 1 | 2010 | 822 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2014 | 4012 | 0.020 |
Why?
|
| Sweden | 1 | 2009 | 1345 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 1996 | 3420 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2015 | 1708 | 0.020 |
Why?
|
| Virginia | 1 | 2006 | 121 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2013 | 2078 | 0.020 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2006 | 242 | 0.020 |
Why?
|
| Dihydrotestosterone | 1 | 2006 | 188 | 0.020 |
Why?
|
| Child | 3 | 2018 | 77679 | 0.020 |
Why?
|
| Kidney Diseases | 1 | 2017 | 2147 | 0.020 |
Why?
|
| Databases, Factual | 2 | 2017 | 7730 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2012 | 3129 | 0.020 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2011 | 838 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2006 | 400 | 0.020 |
Why?
|
| Tyrosine | 1 | 2010 | 1461 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2006 | 295 | 0.020 |
Why?
|
| Ornithine | 1 | 2005 | 78 | 0.020 |
Why?
|
| Echocardiography | 1 | 2018 | 5103 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2008 | 20123 | 0.020 |
Why?
|
| Cell Polarity | 1 | 2008 | 645 | 0.020 |
Why?
|
| DNA Repair | 1 | 2014 | 2046 | 0.020 |
Why?
|
| Flow Cytometry | 2 | 2009 | 5974 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2022 | 12718 | 0.020 |
Why?
|
| Injections, Intralesional | 1 | 2005 | 276 | 0.020 |
Why?
|
| United States | 1 | 2012 | 69867 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 625 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2014 | 5458 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 2002 | 5257 | 0.010 |
Why?
|
| Glucose Intolerance | 1 | 2008 | 577 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2009 | 2297 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2015 | 3469 | 0.010 |
Why?
|
| Consensus | 1 | 2013 | 2958 | 0.010 |
Why?
|
| Extracellular Fluid | 1 | 2005 | 167 | 0.010 |
Why?
|
| Animals, Genetically Modified | 1 | 2008 | 1549 | 0.010 |
Why?
|
| Age Distribution | 1 | 2009 | 2903 | 0.010 |
Why?
|
| Interferons | 1 | 2007 | 706 | 0.010 |
Why?
|
| Neovascularization, Physiologic | 1 | 2010 | 1351 | 0.010 |
Why?
|
| Cell Movement | 1 | 2015 | 5216 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2011 | 2008 | 0.010 |
Why?
|
| Radiography | 1 | 2014 | 7022 | 0.010 |
Why?
|
| Chromatography, Affinity | 1 | 2004 | 549 | 0.010 |
Why?
|
| Age Factors | 2 | 2010 | 18367 | 0.010 |
Why?
|
| Syndrome | 1 | 2009 | 3250 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 2006 | 1525 | 0.010 |
Why?
|
| Age of Onset | 1 | 2009 | 3270 | 0.010 |
Why?
|
| Sodium-Potassium-Chloride Symporters | 1 | 2002 | 102 | 0.010 |
Why?
|
| Contrast Media | 1 | 2015 | 5300 | 0.010 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2002 | 285 | 0.010 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2002 | 135 | 0.010 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2005 | 794 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 2886 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2010 | 2501 | 0.010 |
Why?
|
| Arginine | 1 | 2005 | 944 | 0.010 |
Why?
|
| Cysteine Endopeptidases | 1 | 2004 | 563 | 0.010 |
Why?
|
| Mice, Inbred CBA | 1 | 2002 | 448 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 2002 | 534 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2013 | 3741 | 0.010 |
Why?
|
| Genes, abl | 1 | 2000 | 72 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 1 | 2011 | 2478 | 0.010 |
Why?
|
| Flutamide | 1 | 2001 | 96 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2005 | 1791 | 0.010 |
Why?
|
| Chromones | 1 | 2000 | 154 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2005 | 2335 | 0.010 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2000 | 192 | 0.010 |
Why?
|
| Leukemia, Prolymphocytic | 1 | 2000 | 7 | 0.010 |
Why?
|
| Cycloheximide | 1 | 2000 | 347 | 0.010 |
Why?
|
| Ligases | 1 | 2002 | 333 | 0.010 |
Why?
|
| Multienzyme Complexes | 1 | 2004 | 686 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2002 | 898 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2000 | 191 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2002 | 772 | 0.010 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2001 | 277 | 0.010 |
Why?
|
| Cell Compartmentation | 1 | 2000 | 402 | 0.010 |
Why?
|
| Leukemia, Lymphoid | 1 | 2000 | 313 | 0.010 |
Why?
|
| Forecasting | 1 | 2009 | 2949 | 0.010 |
Why?
|
| Obesity | 1 | 2022 | 12742 | 0.010 |
Why?
|
| G1 Phase | 1 | 2001 | 415 | 0.010 |
Why?
|
| Intracellular Fluid | 1 | 2000 | 203 | 0.010 |
Why?
|
| Interleukin-3 | 1 | 2000 | 441 | 0.010 |
Why?
|
| Half-Life | 1 | 2000 | 659 | 0.010 |
Why?
|
| Endothelial Growth Factors | 1 | 2002 | 694 | 0.010 |
Why?
|
| Doxycycline | 1 | 2000 | 326 | 0.010 |
Why?
|
| Gene Targeting | 1 | 2002 | 880 | 0.010 |
Why?
|
| Protein Precursors | 1 | 2003 | 1154 | 0.010 |
Why?
|
| Linear Models | 1 | 2009 | 5953 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2010 | 3085 | 0.010 |
Why?
|
| Lymphokines | 1 | 2002 | 949 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2001 | 380 | 0.010 |
Why?
|
| Lymphoid Tissue | 1 | 2000 | 455 | 0.010 |
Why?
|
| Lasers | 1 | 2002 | 952 | 0.010 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2000 | 169 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2000 | 433 | 0.010 |
Why?
|
| Antistreptolysin | 1 | 1997 | 7 | 0.010 |
Why?
|
| Sphenoid Bone | 1 | 1999 | 172 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2000 | 1095 | 0.010 |
Why?
|
| Leg Dermatoses | 1 | 1997 | 20 | 0.010 |
Why?
|
| Diffusion | 1 | 2000 | 833 | 0.010 |
Why?
|
| Cadherins | 1 | 2002 | 907 | 0.010 |
Why?
|
| Homeostasis | 1 | 2008 | 3339 | 0.010 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 1997 | 318 | 0.010 |
Why?
|
| Facial Dermatoses | 1 | 1997 | 87 | 0.010 |
Why?
|
| Remission, Spontaneous | 1 | 1997 | 380 | 0.010 |
Why?
|
| Hypopituitarism | 1 | 1999 | 254 | 0.010 |
Why?
|
| Blood Sedimentation | 1 | 1997 | 231 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2004 | 2204 | 0.010 |
Why?
|
| Injections, Intra-Arterial | 1 | 1996 | 193 | 0.010 |
Why?
|
| Biological Transport | 1 | 2000 | 2120 | 0.010 |
Why?
|
| Antibodies, Antinuclear | 1 | 1997 | 326 | 0.010 |
Why?
|
| Dermatitis | 1 | 1997 | 197 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 5221 | 0.010 |
Why?
|
| Sarcoma, Kaposi | 1 | 1998 | 370 | 0.010 |
Why?
|
| Cell Separation | 1 | 2000 | 1751 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 1996 | 548 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 2008 | 3863 | 0.010 |
Why?
|
| Thorax | 1 | 1997 | 547 | 0.010 |
Why?
|
| Arm | 1 | 1997 | 590 | 0.010 |
Why?
|
| Precancerous Conditions | 1 | 2001 | 975 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2005 | 5523 | 0.010 |
Why?
|
| Blood Chemical Analysis | 1 | 1996 | 440 | 0.010 |
Why?
|
| Swine, Miniature | 1 | 1996 | 961 | 0.010 |
Why?
|
| Registries | 1 | 2009 | 8090 | 0.010 |
Why?
|
| Kinetics | 1 | 2001 | 6474 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2000 | 1836 | 0.010 |
Why?
|
| Hodgkin Disease | 1 | 2000 | 1415 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2002 | 2916 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1996 | 1584 | 0.010 |
Why?
|
| Coronary Circulation | 1 | 1996 | 1573 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 19907 | 0.000 |
Why?
|
| Recurrence | 1 | 2000 | 8343 | 0.000 |
Why?
|
| Risk Assessment | 1 | 2009 | 23337 | 0.000 |
Why?
|
| Neurosurgical Procedures | 1 | 1999 | 2003 | 0.000 |
Why?
|
| Patient Selection | 1 | 1999 | 4216 | 0.000 |
Why?
|
| Heart Failure | 1 | 2010 | 10905 | 0.000 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 1997 | 1596 | 0.000 |
Why?
|
| Swine | 1 | 1996 | 5940 | 0.000 |
Why?
|
| Heart Ventricles | 1 | 1996 | 3820 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 2000 | 7179 | 0.000 |
Why?
|
| Infant | 1 | 1997 | 35129 | 0.000 |
Why?
|